ADGM · Adagio Medical
The AI's read
The reported profit does not show stronger sales to customers. European commercial activity remained paused, and most of the profit came from a noncash change in note value. Lower spending helps, but does not solve the lack of sales. The heart-treatment study is fully enrolled, and the FDA approved an expansion. Those are signs of progress, but they do not show that the treatment has reached customers. The Board has started exploring options, with no result reported.